Risk factors in MM: is it time for a revision?

Like Comment
Although therapeutic strategies have been adapted to age and comorbidities for a long time, almost all multiple myeloma (MM) patients currently receive similar treatment whatever their disease risk category. However, high-risk MM patients still constitute an unmet medical need and should benefit from the most efficient drugs combinations. Herein, we review and discuss how to optimally define risk and why a revision of the current definition is urgently needed.


View the article @ Blood (sign-in may be required)


Get PDF with LibKey

ClinOwl

The wider, wiser view for healthcare professionals. ClinOwl signposts the latest clinical content from over 100 leading medical journals.
3460 Contributions
1 Followers
0 Following

No comments yet.